Halozyme Therapeutics Inc (HALO)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 33% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- 12-month trend+57% over the past year+6
- 52-week positionIn the upper quarter of its 52-week range+18
- QualityRevenue growing 41% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is **none** — these headlines are retrospective performance recaps and generic portfolio/stock-screening mentions rather than company-specific news like earnings, product data, M&A, or regulatory action. With no fresh fundamental driver, the probability that the recent 3.3% move continues as a sustained trend over the next few weeks is modest, perhaps around 30–40%, since momentum without a catalyst tends to fade. Informational only — not financial advice.
- Why Women-Run Companies Deserve a Place in Your PortfolioYahoo · 2026-09-24
- Add These 4 GARP Stocks to Your Portfolio to Receive Handsome ReturnsYahoo · 2026-09-23
- If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth NowYahoo · 2026-09-23
- $1000 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth This Much TodayBenzinga · 2026-09-23
- Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?Yahoo · 2026-09-23
Any AI summary is an interpretation of public news, not advice or a price target.